Envision Scientific

What Envision Scientific does

Envision Scientific Private Limited is a Surat, India-based medical device manufacturer incorporated in 2008 (CIN: U24230GJ2008PTC055732) that operates as the sole manufacturing establishment of Concept Medical Group. The company specializes in Drug-Eluting Stents (DES) and Drug-Coated Balloons (DCB) for cardiovascular, peripheral vascular, erectile dysfunction, and arteriovenous fistula indications, producing more than one million devices annually across two Surat-based manufacturing units including a Surat Special Economic Zone facility. Its core technology is a proprietary polymer-free nanocarrier system with specialized nano-coating techniques for targeted sub-micron drug delivery using Sirolimus, protected through trade secrets and embodied in branded platforms including ENVISOLUTION (Abluminus DES+), Nanolute (MagicTouch DCB line), and an Integrated Concept Management System (ICMS) for quality governance.

The product portfolio spans five DES brands (Abluminus DES+, Abluminus NP, Nostrum, Fusion, Mitigator) and four DCB brands (MagicTouch SCB, PTA, AVF, ED), with the company claiming the world's first Sirolimus Coated Balloon for coronary artery disease. Envision Scientific holds regulatory approvals in 60+ markets including US FDA, Japan PMDA, Brazil ANVISA, EU MDR, and India CDSCO, and maintains eight ISO certifications (9001, 13485, 14001, 27001, 45001, 22301, 41001, IEC 17025) alongside IGBC Gold Rating, ESG Registered status, and Great Place to Work recognition.

The business model is B2B medical device sales through a global distributor network and direct engagement with healthcare professionals, with quote-based pricing dependent on volume, region, and product configuration. The company is led by founder and CEO Manish Doshi and runs the world's largest randomized controlled trial in PAD (SirPAD) alongside the US-based MAGICAL BTK IDE pivotal trial — both targeting evidence generation to support US and global commercialization. As a private, vertically integrated manufacturing arm of Concept Medical Group, Envision Scientific's commercial metrics are not separately disclosed.

Name

Envision Scientific

Legal name

Envision Scientific

Website

https://envisionscientific.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

101–250 employees

Short description

Envision Scientific is the Surat, India-based manufacturing arm of Concept Medical Group, producing over one million Drug-Eluting Stents and Drug-Coated Balloons annually using proprietary polymer-free nanocarrier technology, distributed to healthcare professionals in 60+ countries.

Ownership category

akta.pro rank

Product category

Cardiovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)

akta.pro secondary industry

Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)

Keywords

• Drug-eluting stents
• Drug-coated balloons
• Nanocarrier drug delivery
• Cardiovascular medical devices
• Peripheral vascular devices

Headquarters

HQ city

Surat

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Drug-Eluting Stents (DES) Sales: One-time sales of proprietary Drug-Eluting Stents to healthcare facilities and professionals for cardiovascular and peripheral vascular treatments. Revenue generated through direct B2B transactions with hospitals and through distributor networks globally.
2. Drug-Coated Balloons (DCB) Sales: Sales of proprietary Drug-Coated Balloons for various medical indications including cardiovascular, peripheral vascular, erectile dysfunction, and arterio-venous fistula treatments. Products use nano-coating technology for targeted drug delivery.
3. Global Distribution Network: Revenue generated through distribution partnerships and collaborations with organizations worldwide. The company serves 60+ countries through trusted partner networks.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Envision Scientific manufactures Drug-Eluting Stents (DES) and Drug-Coated Balloons (DCB) for cardiovascular, peripheral vascular, erectile dysfunction, and arterio-venous fistula treatments. Products are built on proprietary polymer-free nanocarrier technology and advanced nano-coating techniques, with annual production capacity exceeding one million devices across ISO-certified facilities in Surat, India. The portfolio is distributed to healthcare professionals in 60+ countries through a global network of distributors and direct healthcare institutional supply.

Product overview

Envision Scientific manufactures two core product lines: Drug-Eluting Stents (DES) and Drug-Coated Balloons (DCB) for cardiovascular and peripheral vascular treatments. The DES portfolio includes Abluminus DES+ (using proprietary ENVISOLUTION technology for complex cases), Abluminus NP (polymer-free system), Nostrum (biodegradable coating), Fusion (peripheral application), and Mitigator (fast-degrading polymer). The DCB portfolio features MagicTouch SCB (world's first sirolimus-coated balloon for coronary disease), MagicTouch PTA (peripheral vascular applications), MagicTouch AVF (arteriovenous fistula treatment), and MagicTouch ED (erectile dysfunction treatment). All products utilize proprietary polymer-free nanocarrier technology for targeted drug delivery.

Differentiator

Problem solved

Functional benefit

Brands

• ABLUMINUS: Drug Eluting Stent product line including ABLUMINUS DES+ (designed for diabetes mellitus and acute myocardial infarction patients with coronary artery disease) and ABLUMINUS NP (polymer-free sirolimus eluting stent system).
• MagicTouch
• Nostrum
• Fusion
• Mitigator

Products and services

• Abluminus DES+ Next-generation sirolimus-eluting stent designed for enhanced deliverability and optimal healing in coronary artery disease, featuring proprietary ENVISOLUTION technology to address unmet clinical needs in Diabetes Mellitus and Acute Myocardial Infarction patients with Coronary Artery Disease.
• Abluminus NP Polymer-free sirolimus-eluting stent system with innovative abluminal and fusion coatings for sustained drug delivery, providing comprehensive coverage for optimal vascular repair and arterial lesion management.
• Nostrum Sirolimus-eluting stent with abluminal biodegradable coating designed for precise drug delivery and enhanced vessel healing.
• Fusion Sirolimus-eluting peripheral stent intended to prevent re-narrowing of superficial femoral and popliteal arteries in patients with peripheral artery disease.
• Mitigator Sirolimus-eluting stent with biodegradable polymer that degrades in 6-7 months, offering optimal flexibility and faster healing.
• MagicTouch SCB World's first Sirolimus Coated Balloon for targeted sub-micron drug delivery across the coronary artery disease spectrum, using proprietary nanocarrier technology for effective non-stent treatment.
• MagicTouch PTA Sirolimus-coated balloon with proprietary Nanolute Technology for percutaneous transluminal angioplasty of de-novo, stenotic, and in-stent restenotic lesions in SFA, popliteal, Below The Knee (BTK), and iliac arteries.
• MagicTouch AVF Sirolimus-coated balloon designed with Nanolute Technology for treatment of stenotic lesions in dysfunctional arteriovenous fistula and graft.
• MagicTouch ED Sirolimus-coated balloon for treatment of Erectile Dysfunction in male patients with de novo and restenotic lesions in the internal pudendal, dorsal, or urethral arteries.

Quantifiable outcome

• Over one million drug delivery products manufactured annually
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Lepu Medical: China-based manufacturer of coronary DES (Partner, Nano+) and drug-coated balloons, selling across Asia, EMEA, and Latin America. Comparable as an Asia-headquartered, price-competitive DES/DCB manufacturer pursuing global regulatory clearances; competing against Envision in many of the same 60+ emerging markets.
• Meril Life Sciences: Indian medical-device company producing the BioMime family of sirolimus-eluting stents and the BioMime Morph DES. Competes head-to-head with Envision in emerging markets and increasingly in developed geographies, sharing the 'Indian manufacturer going global' trajectory in DES.
• Sahajanand Medical Technologies (SMT): India-based manufacturer of drug-eluting stents (Yukon Choice, Supraflex, Tigereye) competing directly with Envision in domestic and emerging markets. Most directly comparable as an India-headquartered interventional cardiology device manufacturer targeting coronary and peripheral indications.
• B. Braun: German medical-device manufacturer with the Coroflex ISAR / Coroflex PleaseNeo DES lines and the SeQuent Please paclitaxel-coated balloon — one of the broadest DCB portfolios globally. Closely comparable in product offering, regulatory approach, and target buyer (hospitals/interventional cardiologists), particularly in Europe.
• Concept Medical Research Pvt. Ltd. Envision's parent organization and intellectual-property owner of the ENVISOLUTION and Nanolute platforms. Develops and clinically validates the DES/DCB brands (Abluminus, MagicTouch) that Envision manufactures — the closest functional analog as the source of the company's products, pipeline, and clinical-evidence generation.

Broad incumbents

• Boston Scientific: Global interventional cardiology leader with the SYNERGY and PROMUS DES lines and Ranger/Agent paclitaxel DCB platforms. Directly competes in coronary DES and is the leading force against which Envision's sirolimus DCB is positioned; comparable business model of selling high-margin, regulated drug-device combinations to hospitals.
• Abbott Vascular: Markets the XIENCE family of DES — historically the global DES market-share leader — and competes in coronary and peripheral interventions. Directly comparable as a developer and global seller of drug-eluting stents with regulatory footprints across all 60+ countries Envision serves.
• Medtronic: One of the largest DES manufacturers (Resolute Onyx, Endeavor) and a major player in peripheral interventional cardiology via IN.PACT Admiral DCB and other vascular devices. Competes across all Envision's indications and dwarfs Envision in salesforce scale, clinical evidence, and geographic reach.
• MicroPort Scientific: Shanghai-headquartered interventional cardiology device group with the Firehawk and Firesorb DES franchises and a growing peripheral portfolio. Comparable as a global DES/DCB player with multi-jurisdictional regulatory clearances targeting the same hospital interventional cardiologists.
• Terumo (Cardiovascular Division): Japan-headquartered interventional devices maker with DES franchises and growing peripheral/DCB presence. Competes in coronary DES and PAD DCB; comparable as a globally cleared drug-device combination player with FDA and PMDA approvals, similar to Envision's regulatory footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Envision Scientific